LD Micro Main Event

December 5-7, 2017

Luxe Hotel Sunset Boulevard (Los Angeles)

Taking place in Bel Air, California, LD Micro's annual Main Event conference is a collection of 240 companies from all around the globe, representing all industries. It is the only conference where the most influential names of the buy-side and sell-side gather to collaborate, research and invest.

8:00 am

Manitex International (MNTX)

Manitex International (NASDAQ:MNTX) is a worldwide provider of highly engineered specialized equipment including boom trucks, cranes, and other related industrial equipment. The company's products, manufactured in facilities located in the USA and Europe, are targeted to selected niche markets where their unique designs and engineering excellence fill the needs of customers and provide a competitive advantage. The company consistently adds to its portfolio of branded products and equipment both through internal development and focused acquisitions to diversify and expand sales and profit base while remaining committed to its niche market strategy. For more information, visit the company's website at www.manitexinternational.com.

8:30 am

Pressure Biosciences (PBIO)

Pressure Biosciences (OTC: PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. The company's products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. Over 250 PCT systems are installed worldwide and over 100 publications cite the advantages of the PCT platform over competitive methods. For more information, visit the company's website at www.pressurebiosciences.com.

Eleven Biotherapeutics (EBIO)

Eleven Biotherapeutics (NASDAQ: EBIO) is a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based upon the company's targeted protein therapeutics (TPTs) platform. The company's TPTs incorporate a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule in order to achieve focused tumor cell killing. The company believes its TPTs provide effective tumor targeting with broader cancer cell-killing properties than are achievable with small molecule payloads that require tumor cell proliferation and face multi-drug resistance mechanisms. The company believes that its TPT's cancer cell-killing properties promote an anti-tumor immune response that will potentially combine well with immune oncology drugs such as checkpoint inhibitors. For more information, visit the company's website at www.elevenbio.com.

Cesca Therapeutics (KOOL)

Cesca Therapeutics (NASDAQ: KOOL) is a regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the vascular, cardiology and orthopedic markets. For more information, visit the company's website at www.cescatherapeutics.com.

Helios and Matheson Analytics (HMNY)

Helios and Matheson Analytics (NASDAQ: HMNY) is a provider of information technology services and solutions, offering a range of technology platforms focusing on big data, artificial intelligence, business intelligence, social listening, and consumer-centric technology. Its holdings include RedZone Map™, a safety and navigation app for iOS and Android users, and a community-based ecosystem that features a socially empowered safety map app that enhances mobile GPS navigation using advanced proprietary technology. Through TrendIt, HMNY has acquired technology addressing crowd and migration patterns and consumer behavior in real-time. The patented technology predicts population behavior, along with a crowd's population size, origin and destination. For more information, visit the company's website at www.hmny.com.

9:00 am

OncoSec Medical (ONCS)

OncoSec Medical (NASDAQ: ONCS) is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for several indications, including metastatic melanoma, and triple-negative breast cancer. For more information, visit the company website at www.oncosec.com.


FISION (OTC: FSSN) is a provider of agile marketing software that simplifies collaboration across global organizations, and more effectively manages brand and marketing content. FISION allows marketing and sales teams to work better together by enabling them to more quickly and easily create, distribute and measure the performance of compelling, localized, on-brand communications. FISION's patented technology brings capabilities to clients across more than 20 countries, which includes some of the world's largest corporations in healthcare, hospitality, financial/insurance, software and technology. For more information, visit the company's website at www.fisiononline.com.

Onconova Therapeutics (ONTX)

Onconova Therapeutics (NASDAQ:ONTX) is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes. Onconova's lead candidate, Rigosertib, is a proprietary Phase 3 small molecule agent, which the company believes blocks cellular signaling by targeting RAS effector pathways. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in the clinical stage and several pre-clinical programs. For more information, visit the company's website at www.onconova.com.

9:30 am

Arcimoto (FUV)

Arcimoto (NASDAQ: FUV) develops and designs electric vehicles currently producing a three-wheeled motorcycle called the SRK. For more information, visit the company's website at www.arcimoto.com.

ImmunoCellular Therapeutics (IMUC)

ImmunoCellular Therapeutics (NYSE: IMUC) is a clinical-stage company developing immune-based therapies for the treatment of brain and other cancers. The company's lead product candidate, ICT-107, is a patient-specific, dendritic cell-based immunotherapy targeting glioblastoma and is currently being studied in an international Phase 3 trial. ImmunoCellular's pipeline also includes: ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting CD133 found in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting ovarian cancer; and the Stem-to-T-cell research program which engineers hematopoietic stem cells to generate cytotoxic T cells. For more information, visit the company's website at imuc.com.

Navidea Biopharmaceuticals (NAVB)

Navidea Biopharmaceuticals (NYSE: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its ManoceptTM platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea's Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc 99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. For more information, visit the company website at www.navidea.com.

10:00 am

RadNet (RDNT)

RadNet (NASDAQ: RDNT) is a national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 298 owned and/or operated outpatient imaging centers. RadNet's core markets include California, Maryland, Delaware, New Jersey and New York. In addition, RadNet provides radiology information technology solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. For more information, visit the company's website at www.radnet.com.

Digital Ally (DGLY)

Digital Ally (NASDAQ: DGLY) specializes in the design and manufacturing of the highest quality video recording equipment and video analytic software. Digital Ally pushes the boundaries of technology in industries such as law enforcement, emergency management, commercial fleets, and consumer use. Digital Ally's complete product solutions include in-car and body cameras, cloud and local management software, and automatic recording technology. These products work seamlessly together and are simple to install and operate. Digital Ally products are sold by domestic direct sales representatives and international distributors worldwide. For more information, visit the company's website at www.digitalallyinc.com.

Ampio Pharmaceuticals (AMPE)

Ampio Pharmaceuticals (NYSE MKT: AMPE) is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The company is developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability. For more information, visit the company's website at ampiopharma.com.

10:30 am

Caladrius Biosciences (CLBS)

Caladrius Biosciences (NASDAQ: CLBS) is a clinical stage development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and select cardiovascular indications. The company is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes, in a currently enrolling Phase 2 trial. For more information, visit the company's website at www.caladrius.com.

Biomerica (BMRA)

Biomerica (NASDAQ: BMRA) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care and in hospital/clinical laboratories for the early detection of medical conditions and diseases. Biomerica primarily focuses on products for gastrointestinal disease, diabetes and esoteric testing. The Biomerica InFoods IBS product identifies patient specific foods that when removed may alleviate an individual's IBS symptoms. This patent-pending, diagnostic-guided therapy is designed to allow for a patient-specific, guided dietary regimen to improve Irritable Bowel Syndrome (IBS) outcomes. For more information, visit the company's website at www.biomerica.com.

Ritter Pharmaceuticals (RTTR)

Ritter Pharmaceuticals (NASDAQ: RTTR) develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. The Company is further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing a variety of conditions including: gastrointestinal diseases, immuno-oncology, metabolic, and liver disease. For more information, visit the company's website at www.RitterPharma.com.

US Nuclear (UCLE)

US Nuclear (OTC: UCLE) is principally engaged through its subsidiaries, operating two leading nuclear radiation detection companies, Overhoff Technology Corp. and Optron Scientific Company Inc. The company designs, manufactures and markets branded, full line radiation detection and specialized advanced tritium technology for the nuclear energy industry and for emerging technological processes such as Thorium and Molten Salt (MSR) reactor technologies both domestically and internationally to customers such as United States Government Agencies, the U.S. Military, Homeland Security, Scientific Laboratories, Universities, Hospitals, nuclear reactor facilities in the United States, China, Canada, South Korea, Argentina, Russia and others. For more information, visit the company's website at www.new.usnuclearcorp.com.

11:00 am

Differential Brands Group, Inc. (DFBG)

Differential Brands Group, Inc. (NASDAQ: DFBG) Differential Brands Group (NASDAQ: DFBG) is a platform that focuses on branded operating companies in the premium apparel, footwear and accessories sectors. Company focus is on organically growing in-house brands through a global, omni-channel distribution strategy while continuing to seek opportunities to acquire accretive, complementary, premium brands. Current brands include Hudson®, a designer and marketer of premium, branded denim and apparel, Robert Graham®, an eclectic apparel and accessories brand, and SWIMS®, a Scandinavian lifestyle brand best known for its water-friendly footwear, apparel and accessories. For more information, visit the company's website at www.differentialbrandsgroup.com.

The Crypto Company (CRCW)

The Crypto Company (OTC: CRCW) one of the first publicly traded technology companies in the digital currencies and blockchain sector, offers a portfolio of digital assets, technologies, and consulting services to the blockchain and cryptocurrency markets. Shareholders in The Crypto Company gain diversified exposure to this exponentially growing asset class. For more information, visit the company's website at www.thecryptocompany.com.

Cinedigm (CIDM)

Cinedigm (NASDAQ: CIDM) powers custom content solutions to the world's largest retail, media and technology companies. Cinedigm provides premium feature films and series to digital platforms including iTunes, Netflix, and Amazon, cable and satellite providers including Comcast, Dish Network and DirecTV, and major retailers including Walmart and Target. Leveraging Cinedigm's unique capabilities, content and technology, the company has emerged as a leader in the fast-growing over-the-top channel business, with four channels under management that reach hundreds of millions of devices while also providing premium content and service expertise to the entire OTT ecosystem. For more information, visit the company's website at www.cinedigm.com.

11:30 am

Propanc Biopharma (PPCB)

Propanc Biopharma (OTC: PPCB) is a clinical stage biopharmaceutical company developing new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers. Propanc has developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Propanc's products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, the company intends to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, it intends to develop products to treat early stage cancer, pre-cancerous diseases and as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit the company's website at www.propanc.com.

VivoPower International PLC (VVPR)

VivoPower International PLC (NASDAQ: VVPR) engages in the provision of solar power generation services. Its business model encompasses power support services, rooftop CIG BTO and ground mount utility BTO sales, energy efficient and storage and smart green power services and technology and new energy investments. VivoPower's business model is to operate solar power assets to provide commercial, industrial and government customers with renewable energy. For more information, visit the company's website at www.vivopower.com.


HUTN (OTC: HUTN) is the new name of EF Hutton's holding company. EF Hutton Financial, a subsidiary of EF Hutton America (HUTN) is a leader in digital finance and online investment services. EF Hutton offers "no commission" investment services and a "no commission" trade execution that allows traders to pay one price for a month of trading – like an "all you can eat" plan for trading. Recently, EF Hutton announced plans to roll out a mobile platform that will extend its services. EF Hutton, is a legendary brand in financial services known for its attention to clients. For more information, visit the company's website at www.efhutton.com.

12:00 pm

Reign Sapphire (RGNP)

Reign Sapphire (OTC: RGNP) is a Beverly Hills-based, D2C branded and custom jewelry company with three niche brands: Reign Sapphires: ethically produced, millennial targeted sapphire jewelry, Coordinates Collection: custom jewelry, inscribed with location coordinates commemorating life's special moments, and Le Bloc: classic customized jewelry. For more information, visit the company's website at www.reignsc.com.

Contact us: 212.418.1217